[go: up one dir, main page]

NO316256B1 - Anvendelse av 1-(2-naft-2-yletyl)-4-(3-trifluormetylfenyl)- 1,2,3,6-tetrahydropyridin for fremstilling av legemidler for behandling avamyotrof lateral sklerose - Google Patents

Anvendelse av 1-(2-naft-2-yletyl)-4-(3-trifluormetylfenyl)- 1,2,3,6-tetrahydropyridin for fremstilling av legemidler for behandling avamyotrof lateral sklerose Download PDF

Info

Publication number
NO316256B1
NO316256B1 NO19981856A NO981856A NO316256B1 NO 316256 B1 NO316256 B1 NO 316256B1 NO 19981856 A NO19981856 A NO 19981856A NO 981856 A NO981856 A NO 981856A NO 316256 B1 NO316256 B1 NO 316256B1
Authority
NO
Norway
Prior art keywords
naphth
ylethyl
pharmaceutically acceptable
treatment
trifluoromethylphenyl
Prior art date
Application number
NO19981856A
Other languages
English (en)
Norwegian (no)
Other versions
NO981856D0 (no
NO981856L (no
Inventor
Patrice Douillet
Jacqueline Fournier
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9512635A external-priority patent/FR2740343B1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of NO981856D0 publication Critical patent/NO981856D0/no
Publication of NO981856L publication Critical patent/NO981856L/no
Publication of NO316256B1 publication Critical patent/NO316256B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
NO19981856A 1995-10-26 1998-04-24 Anvendelse av 1-(2-naft-2-yletyl)-4-(3-trifluormetylfenyl)- 1,2,3,6-tetrahydropyridin for fremstilling av legemidler for behandling avamyotrof lateral sklerose NO316256B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9512635A FR2740343B1 (fr) 1995-10-26 1995-10-26 Utilisation de la 1-(2-napht-2-yl-ethyl)-4- (3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique
FR9607336 1996-06-13
PCT/FR1996/001674 WO1997015304A1 (fr) 1995-10-26 1996-10-25 Utilisation de la 1-(2-napht-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de la sclerose laterale amyotrophique

Publications (3)

Publication Number Publication Date
NO981856D0 NO981856D0 (no) 1998-04-24
NO981856L NO981856L (no) 1998-06-11
NO316256B1 true NO316256B1 (no) 2004-01-05

Family

ID=26232287

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19981856A NO316256B1 (no) 1995-10-26 1998-04-24 Anvendelse av 1-(2-naft-2-yletyl)-4-(3-trifluormetylfenyl)- 1,2,3,6-tetrahydropyridin for fremstilling av legemidler for behandling avamyotrof lateral sklerose

Country Status (27)

Country Link
US (1) US6043251A (is)
EP (1) EP0866704B1 (is)
JP (1) JP3468526B2 (is)
KR (1) KR100472793B1 (is)
CN (1) CN1104241C (is)
AT (1) ATE200423T1 (is)
AU (1) AU719342B2 (is)
BR (1) BR9611124A (is)
CA (1) CA2235747C (is)
CY (1) CY2279B1 (is)
CZ (1) CZ293360B6 (is)
DE (1) DE69612510T2 (is)
DK (1) DK0866704T3 (is)
EE (1) EE04177B1 (is)
ES (1) ES2159362T3 (is)
GR (1) GR3036027T3 (is)
HU (1) HU222039B1 (is)
IL (1) IL124091A (is)
IS (1) IS1961B (is)
NO (1) NO316256B1 (is)
NZ (1) NZ320355A (is)
PT (1) PT866704E (is)
SI (1) SI0866704T1 (is)
SK (1) SK284099B6 (is)
TR (1) TR199800717T2 (is)
UA (1) UA57004C2 (is)
WO (1) WO1997015304A1 (is)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2782008B1 (fr) * 1998-08-07 2003-04-25 Sod Conseils Rech Applic Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sclerose laterale amyotrophique
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
HUP0500001A3 (en) * 2001-12-11 2005-11-28 Univ Virginia Use of pramipexole to treat amyotrophic lateral sclerosis
KR101130212B1 (ko) * 2002-03-27 2012-04-13 파이토팜 피엘씨 사포게닌 및 그 유도체의 치료 방법 및 사용법
EP1917014B1 (en) * 2005-08-15 2009-10-07 University Of Virginia Patent Foundation Neurorestoration with r(+) pramipexole
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
DK2026803T3 (da) 2006-05-16 2012-04-16 Knopp Neurosciences Inc Sammensætninger af R(+) og S(-) pramipexol og fremgangsmåder til anvendelse heraf
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
AU2008224844B2 (en) 2007-03-14 2012-08-09 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
CA2734491A1 (en) * 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
ES3043076T3 (en) 2013-07-12 2025-11-24 Areteia Therapeutics Inc Treating elevated levels of eosinophils and/or basophils
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
EP3033081B1 (en) 2013-08-13 2021-05-12 Knopp Biosciences LLC Compositions and methods for treating chronic urticaria
AU2014306683B2 (en) 2013-08-13 2017-10-12 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662355B1 (fr) * 1990-05-22 1994-11-10 Sanofi Sa Utilisation de la 1-[2-(2-naphtyl)ethyl]-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine pour la preparation de medicaments destines au traitement de troubles cerebraux et neuronaux.
FR2672213B1 (fr) * 1991-02-05 1995-03-10 Sanofi Sa Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres.
FR2672731A1 (fr) * 1991-02-07 1992-08-14 France Telecom Procede d'oxydation localisee enterree d'un substrat de silicium et circuit integre correspondant.
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.

Also Published As

Publication number Publication date
CZ129698A3 (cs) 1998-07-15
JP3468526B2 (ja) 2003-11-17
CA2235747A1 (en) 1997-05-01
HUP9802945A2 (hu) 1999-04-28
EE04177B1 (et) 2003-12-15
ATE200423T1 (de) 2001-04-15
HK1016904A1 (en) 1999-11-12
HU222039B1 (hu) 2003-03-28
JPH11515012A (ja) 1999-12-21
DE69612510D1 (de) 2001-05-17
IS4722A (is) 1998-04-21
SI0866704T1 (en) 2001-08-31
SK284099B6 (sk) 2004-09-08
PT866704E (pt) 2001-07-31
NZ320355A (en) 2000-03-27
AU7308496A (en) 1997-05-15
EE9800132A (et) 1998-10-15
DK0866704T3 (da) 2001-07-16
EP0866704B1 (fr) 2001-04-11
SK52698A3 (en) 1998-09-09
US6043251A (en) 2000-03-28
ES2159362T3 (es) 2001-10-01
KR100472793B1 (ko) 2005-06-16
MX9803271A (es) 1998-09-30
AU719342B2 (en) 2000-05-04
CY2279B1 (en) 2003-07-04
CZ293360B6 (cs) 2004-04-14
NO981856D0 (no) 1998-04-24
NO981856L (no) 1998-06-11
HUP9802945A3 (en) 1999-05-28
EP0866704A1 (fr) 1998-09-30
DE69612510T2 (de) 2001-11-22
WO1997015304A1 (fr) 1997-05-01
CN1202826A (zh) 1998-12-23
IL124091A (en) 2003-10-31
IS1961B (is) 2004-11-15
BR9611124A (pt) 1999-05-11
GR3036027T3 (en) 2001-09-28
TR199800717T2 (xx) 1998-09-21
KR19990067057A (ko) 1999-08-16
CA2235747C (en) 2006-01-03
UA57004C2 (uk) 2003-06-16
CN1104241C (zh) 2003-04-02

Similar Documents

Publication Publication Date Title
NO316256B1 (no) Anvendelse av 1-(2-naft-2-yletyl)-4-(3-trifluormetylfenyl)- 1,2,3,6-tetrahydropyridin for fremstilling av legemidler for behandling avamyotrof lateral sklerose
DE60132723T2 (de) Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
DE60009697T2 (de) Verwendung von 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazin und dessen physiologisch akzeptablen salzen zur behandlung von bipolaren krankheiten und manie
US20060241133A1 (en) Electrically variable pneumatic structural element
EP4531850A1 (en) Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction
KR20180034442A (ko) 아캄프로세이트와 d-사이클로세린을 사용한 병용 치료
CN110691593B (zh) 脊髓小脑变性症预防或治疗剂
TWI892226B (zh) 用於治療多巴胺性cns病症之ly3154207劑量療法
DE69907220T2 (de) Verwendung von substanz p antagonisten zur behandlung des chronischen ermüdungssyndroms und/oder der fibromyalgie
TWI289060B (en) Pharmaceutical composition for improving the recovery of post-stroke patients
JP2005501108A (ja) 神経変性治療におけるネフィラセタムの使用
WO2011110608A1 (en) Treatment of dementia of alzheimer's type with masitinib
MXPA98003271A (en) Use of 1- (2-naft-2-iletil) -4- (3-trifluorometilfenil) -1, 2, 3, 6-tetrahydropiridine for the preparation of drugs for the treatment of lateral sclerosis amiotrof
Gasbarrini et al. Posatirelin for the treatment of degenerative and vascular dementia: results of explanatory and pragmatic efficacy analyses
EP0626849A1 (en) Brofaromine as an agent for treating post-traumatic stress
JPH06107544A (ja) コリン作動性神経不全の改善・治療薬
EP1773340A2 (en) Pharmaceutical composition of (+)-erythro-mefloquine and its use in the treatment of an inflammatory condition
HK40018453B (en) Agent for preventing or treating spinocerebellar ataxia
HK1016904B (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
WO2004032932A1 (de) Verwendung von 5-ht2-rezeptorantagonisten zur behandlung von schlafstörungen